256 related articles for article (PubMed ID: 33998890)
1. Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood-Brain Barrier Under Ischemic Conditions.
Stone NL; England TJ; O'Sullivan SE
Cannabis Cannabinoid Res; 2021 Aug; 6(4):315-326. PubMed ID: 33998890
[No Abstract] [Full Text] [Related]
2. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors.
Hind WH; England TJ; O'Sullivan SE
Br J Pharmacol; 2016 Mar; 173(5):815-25. PubMed ID: 26497782
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
4. The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β-evoked neurotoxicity and changes in cell morphology in PC12 cells.
Marsh DT; Sugiyama A; Imai Y; Kato R; Smid SD
Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):293-309. PubMed ID: 37697481
[TBL] [Abstract][Full Text] [Related]
5. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol.
Pagano E; Montanaro V; Di Girolamo A; Pistone A; Altieri V; Zjawiony JK; Izzo AA; Capasso R
Nat Prod Commun; 2015 Jun; 10(6):1009-12. PubMed ID: 26197538
[TBL] [Abstract][Full Text] [Related]
6. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures.
Rosenthaler S; Pöhn B; Kolmanz C; Huu CN; Krewenka C; Huber A; Kranner B; Rausch WD; Moldzio R
Neurotoxicol Teratol; 2014; 46():49-56. PubMed ID: 25311884
[TBL] [Abstract][Full Text] [Related]
7. A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT
Echeverry C; Prunell G; Narbondo C; de Medina VS; Nadal X; Reyes-Parada M; Scorza C
Neurotox Res; 2021 Apr; 39(2):335-348. PubMed ID: 32886342
[TBL] [Abstract][Full Text] [Related]
8. The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke.
Shan Y; Tan S; Lin Y; Liao S; Zhang B; Chen X; Wang J; Deng Z; Zeng Q; Zhang L; Wang Y; Hu X; Qiu W; Peng L; Lu Z
J Neuroinflammation; 2019 Nov; 16(1):242. PubMed ID: 31779652
[TBL] [Abstract][Full Text] [Related]
9. Microvascular endothelial cells-derived microvesicles imply in ischemic stroke by modulating astrocyte and blood brain barrier function and cerebral blood flow.
Pan Q; He C; Liu H; Liao X; Dai B; Chen Y; Yang Y; Zhao B; Bihl J; Ma X
Mol Brain; 2016 Jun; 9(1):63. PubMed ID: 27267759
[TBL] [Abstract][Full Text] [Related]
10. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
Deiana S; Watanabe A; Yamasaki Y; Amada N; Arthur M; Fleming S; Woodcock H; Dorward P; Pigliacampo B; Close S; Platt B; Riedel G
Psychopharmacology (Berl); 2012 Feb; 219(3):859-73. PubMed ID: 21796370
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoids modulate human blood-brain barrier permeability in vitro.
Hind WH; Tufarelli C; Neophytou M; Anderson SI; England TJ; O'Sullivan SE
Br J Pharmacol; 2015 Jun; 172(12):3015-27. PubMed ID: 25651941
[TBL] [Abstract][Full Text] [Related]
12. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.
Iannotti FA; Hill CL; Leo A; Alhusaini A; Soubrane C; Mazzarella E; Russo E; Whalley BJ; Di Marzo V; Stephens GJ
ACS Chem Neurosci; 2014 Nov; 5(11):1131-41. PubMed ID: 25029033
[TBL] [Abstract][Full Text] [Related]
13. Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ
Piscitelli F; Pagano E; Lauritano A; Izzo AA; Di Marzo V
Anal Chem; 2017 Apr; 89(8):4749-4755. PubMed ID: 28343385
[TBL] [Abstract][Full Text] [Related]
14. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
Oláh A; Markovics A; Szabó-Papp J; Szabó PT; Stott C; Zouboulis CC; Bíró T
Exp Dermatol; 2016 Sep; 25(9):701-7. PubMed ID: 27094344
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of interleukin-9 ameliorates experimental stroke by repairing the blood-brain barrier via down-regulation of astrocyte-derived vascular endothelial growth factor-A.
Tan S; Shan Y; Lin Y; Liao S; Zhang B; Zeng Q; Wang Y; Deng Z; Chen C; Hu X; Peng L; Qiu W; Lu Z
FASEB J; 2019 Mar; 33(3):4376-4387. PubMed ID: 30694693
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
[TBL] [Abstract][Full Text] [Related]
17. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Hill TD; Cascio MG; Romano B; Duncan M; Pertwee RG; Williams CM; Whalley BJ; Hill AJ
Br J Pharmacol; 2013 Oct; 170(3):679-92. PubMed ID: 23902406
[TBL] [Abstract][Full Text] [Related]
18. Ligustilide Ameliorates the Permeability of the Blood-Brain Barrier Model In Vitro During Oxygen-Glucose Deprivation Injury Through HIF/VEGF Pathway.
Wu S; Wang N; Li J; Wang G; Seto SW; Chang D; Liang H
J Cardiovasc Pharmacol; 2019 May; 73(5):316-325. PubMed ID: 30855407
[TBL] [Abstract][Full Text] [Related]
19. Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression.
Li YN; Pan R; Qin XJ; Yang WL; Qi Z; Liu W; Liu KJ
J Neurochem; 2014 Apr; 129(1):120-9. PubMed ID: 24251624
[TBL] [Abstract][Full Text] [Related]
20. Hypertonic saline alleviates experimentally induced cerebral oedema through suppression of vascular endothelial growth factor and its receptor VEGFR2 expression in astrocytes.
Huang L; Cao W; Deng Y; Zhu G; Han Y; Zeng H
BMC Neurosci; 2016 Oct; 17(1):64. PubMed ID: 27733124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
